A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis

Palbociclib 3-weeks-on/1-week-off, combined with hormonal therapy, is approved for hormone receptor positive (HR+)/HER2-negative (HER2−) advanced/metastatic breast cancer (MBC). Neutropenia is the most frequent adverse event (AE). We aim to determine whether an alternative 5-days-on/2-days-off weekl...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnamurthy, Jairam, Luo, Jingqin, Suresh, Rama, Ademuyiwa, Foluso, Rigden, Caron, Rearden, Timothy, Clifton, Katherine, Weilbaecher, Katherine, Frith, Ashley, Roshal, Anna, Tandra, Pavan K., Cherian, Mathew, Summa, Tracy, Haas, Brittney, Thomas, Shana, Hernandez-Aya, Leonel, Bergqvist, Mattias, Peterson, Lindsey, Ma, Cynthia X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938484/
https://www.ncbi.nlm.nih.gov/pubmed/35314693
http://dx.doi.org/10.1038/s41523-022-00399-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938484/
https://www.ncbi.nlm.nih.gov/pubmed/35314693
http://dx.doi.org/10.1038/s41523-022-00399-w

Ejemplares similares